Rapamycin Protects Against High Fat Diet–Induced Obesity in C57BL/6J Mice
Tóm tắt
Từ khóa
Tài liệu tham khảo
1 Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. Ann Med. 2007;39:482–494.
5 Asnaghi L, Bruno P, Priulla M, Nicolin A. mTOR: a protein kinase switching between life and death. Pharmacol Res. 2004;50:545–549.
6 Soliman GA. The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol. 2005;16:317–323.
8 Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005;146:1473–1481.
12 Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, et al. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant. 2006;20 17:S30–S43.
13 Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O’Driscoll G, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700.
14 Garber K. Rapamycin’s resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst. 2001;93:1517–1579.
15 Bell A, Grunder L, Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res. 2000;8:249–254.
16 Sipula IJ, Brown NF, Perdomo G. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism. 2006;55:1637–1644.
17 Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm. 2004;61:565–585.
18 Mathe D, Adam R, Malmendier C, Gigou M, Lontie JF, Dubois D, et al. Prevalence of dyslipidemia in liver transplant recipients. Transplantation. 1992;54:167–170.
19 Brattström C, Wilczek HE, Tydén G, Böttiger Y, Säwe J, Groth CG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc. 1998;30:3950–3951.
21 Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;15:7291–7297.
22 Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46:454–460.
25 Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D, et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology. 2003;38:436–442.
32 Munzberg H, Bjornholm M, Bates SH, Myers MG Jr. Leptin receptor action and mechanisms of leptin resistance. Cell Mol Life Sci. 2005;62:642–652.
34 Mauvoisin D, Rocque G, Arfa O, Radenne A, Boissier P, Mounier C. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J Cell Commun Signal. 2007;1:113–125.
35 El-Chaar D, Gagnon A, Sorisky A. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int J Obes. 2004;28:191–198.
36 Edgar BA, Nijhout HF. Growth and cell cycle in Drosophila. In: Hall MN, Martin RM, Thomas G, editors. Cell growth: control of cell size. 1st ed. Cold Spring Harbor Laboratory Press; 2004. p. 43–44.
39 Wang T, Hartzell DL, Rose BS, Flatt WP, Hulsey MG, Menon NK, et al. Metabolic responses to intracerebroventricular leptin and restricted feeding. Physiol Behav. 1999;65:839–848.
40 Houseknecht KL, Baile CA, Matteri RL, Spurlock ME. The biology of leptin: a review. J Anim Sci. 1998;76:1405–1420.
45 Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl. 2001;7:S13–S21.
46 O’Connor JC, Freund GG. Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake. Metabolism. 2003;52:666–674.
48 Hribal ML, Perego L, Lovari S, Andreozzi F, Menghini R, Perego C, et al. Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. FASEB J. 2003;17:1340–1342.
50 Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128–3135.